west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "支原体肺炎" 5 results
  • 肺炎支原体肺炎并冷凝集素病致急性肺栓塞一例

    Release date:2016-09-13 04:07 Export PDF Favorites Scan
  • Moxifloxacin for Mycoplasma Pneumonia: A Meta-analysis

    ObjectiveTo systemically review the efficacy and safety of moxifloxacin for mycoplasma pneumoniae. MethodsSuch databases as PubMed, The Cochrane library (Issue 4, 2014), ISI, CBM, CNKI, VIP and WanFang Data were searched from inception to April 2014 for randomized controlled trials (RCTs) concerning moxifloxacin for mycoplasma pneumoniae. Two reviewers screened literature according to the inclusion and exclusion criteria, extract data, and assess methodological quality of included studies. Then meta-analysis was performed using RevMan 5.2 software. ResultsA total of 16 RCTs involving 1 401 patients were included. The results of meta-analysis showed that:compared with erythrocin or azithromycin, moxifloxacin had higher recovery rate (OR=2.35, 95%CI 1.76 to 3.15, P<0.000 01), higher bacterium negative rate (OR=3.74, 95%CI 1.76 to 7.96, P=0.000 6), and shorter fever clearance time (MD=-1.07, 95%CI -1.43 to -0.71, P<0.000 01); compared with azithromycin alone, moxifloxacin combined with azithromycin had higher recovery rate (OR=1.63, 95%CI 1.09 to 2.42, P=0.02), higher bacterium negative rate (OR=5.78, 95%CI 2.41 to 13.84, P<0.000 1), and shorter fever clearance time (MD=-0.99, 95%CI -1.52 to -0.47, P=0.000 2). In addition, there was a lower incidence of liver damage (OR=0.16, 95%CI 0.04 to 0.72, P=0.02) in patients who took moxifloxacin compared with erythromycin or azithromycin. No significant difference was found in the incidence of gastrointestinal adverse reaction between the two groups. ConclusionMoxifloxacin for mycoplasma pneumonia is more effective than macrolides (erythrocin or azithromycin) with a lower incidence of adverse reaction. Due to limited quantity and quality of the included studies, the above conclusion should be further verified by conducting more high quality, large scale, multicentre RCTs.

    Release date: Export PDF Favorites Scan
  • Risk factors for refractory mycoplasma pneumoniae pneumonia in children: a systematic review

    ObjectiveTo systematically review the risk factors of refractory mycoplasma pneumoniae pneumonia (RMPP) in children. MethodsPubMed, The Cochrane Library, EMbase, CNKI, CBM, VIP, and WanFang Data databases were electronically searched for case-control studies and cohort studies on the risk factors of RMPP in children from inception to March 2021. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using RevMan 5.3 software. ResultsA total of 27 case-control studies involving 3 967 children with RMPP and 11 613 children with common MPP were included. The results of meta-analysis showed that heat course (OR=2.07, 95%CI 1.98 to 2.16, P<0.000 01), length of hospital stay (OR=1.42, 95%CI 1.14 to 1.69, P<0.000 01), recurrent respiratory tract infection (OR=8.51, 95%CI 6.15 to 11.77, P<0.000 01), level of IL-6 (OR=21.95, 95%CI 20.85 to 23.06, P<0.000 01), level of CRP (OR=2.41, 95%CI 1.94 to 2.87, P<0.000 01), level of LDH (OR=0.79, 95%CI 0.53 to 1.06, P<0.000 01), level of ESR (OR=2.65, 95%CI 1.13 to 4.18, P=0.000 6), combined pleural effusion (OR=9.42, 95%CI 3.65 to 24.31, P<0.000 01), combined with extrapulmonary complications (OR=3.33, 95%CI 2.42 to 4.58, P<0.000 01), large lung consolidation (OR=12.31, 95%CI 5.42 to 27.99, P<0.000 01) were the risk factors for RMPP. ConclusionsCurrent evidence indicates that heat course, length of hospital stay, repeated respiratory tract infection, high level of IL-6, high level of CRP, high level of LDH, high level of ESR, combined pleural effusion, combined extrapulmonary complications, and large lung consolidation are risk factors for children with RMPP. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions.

    Release date: Export PDF Favorites Scan
  • 妊娠期重症支原体肺炎并噬血细胞综合征一例并文献复习

    目的 探讨成人重症支原体肺炎的临床表现、诊断、治疗及预后,提高临床医师对此病的认识。方法 报道1例妊娠期重症支原体肺炎并噬血细胞综合征患者的病史、临床表现及诊治经过,并复习国内外相关文献报道。结果 患者25岁,妊娠14周,临床症状为高热、咳嗽、胸闷,血常规提示贫血、血小板减少,血气分析提示Ⅰ型呼吸衰竭,胸部CT提示左肺大片实变伴胸腔积液,腹部彩色多普勒超声提示脾脏轻度肿大,肺炎支原体IgM、IgG升高,肺泡灌洗液宏基因高通量测序肺炎支原体序列数显著升高,气管镜活检组织肺炎支原体DNA升高,血清铁蛋白升高,骨髓穿刺可见组织细胞吞噬成熟红细胞及血小板,诊断重症支原体肺炎明确,同时符合噬血细胞综合征2004诊断标准,给予莫西沙星、糖皮质激素、丙种球蛋白等治疗后好转出院。文献检索成人肺炎支原体并噬血细胞综合征,中文期刊无相关报道,外文期刊仅有5篇,所有患者给予大环内酯类或喹诺酮类药物联合糖皮质激素等治疗,均预后良好。结论 成人重症支原体肺炎容易合并肺外损伤,联合糖皮质激素能够降低免疫反应,缩短病程,改善预后。

    Release date: Export PDF Favorites Scan
  • 多西环素用于喹诺酮类治疗失败的大环内酯类耐药肺炎支原体肺炎一例

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content